Neil A O'Brien (Neil O'Brien)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Breast cancer research : BCR

Molecular cancer therapeutics

Cancer immunology research

David Geffen School of Medicine at UCLA

This page only lists publications with an associated author ORCID identifier.

Affiliation History

David Geffen School of Medicine at UCLA Jul 01 2012

United States

Assistant Professor :: Medicine

Publications

Rohan Diwanji, Neil A O'Brien, Jiyoung E Choi, Beverly Nguyen, Tyler Laszewski, Angelo L Grauel, Zheng Yan, Xin Xu, Jincheng Wu, David A Ruddy, Michelle Piquet, Marc R Pelletier, Alexander Savchenko, LaSalette Charette, Vanessa Rodrik-Outmezguine, Jason Baum, John M Millholland, Connie C Wong, Anne-Marie Martin, Glenn Dranoff, Iulian Pruteanu-Malinici, Viviana Cremasco, Catherine Sabatos-Peyron, Pushpa Jayaraman
Targeting the IL-1β pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses. Cancer immunology research (2023)
Neil A O'Brien, Martina S J McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M Madrid, Timothy R Donahue, John A Glaspy, Leonard Presta, Dennis J Slamon
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-drug Conjugate for Treatment of CLDN18.2 Positive Cancers. Molecular cancer therapeutics (2023)
Martina S J McDermott, Neil A O'Brien, Benjamin Hoffstrom, Ke Wei Gong, Ming Lu, Jun Zhang, Tong Luo, Min Liang, Weiping Jia, Jenny Hong, Kevin Chau, Simon Davenport, Bin Xie, Michael F Press, Richard Panayiotou, Abram Handly-Santana, Joan S Brugge, Leonard Presta, John A Glaspy, Dennis J Slamon
Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Zev A Wainberg, Arun S Singh, Gottfried E Konecny, Kelly E McCann, J Randolph Hecht, Jonathan Wade Goldman, Bartosz Chmielowski, Richard S Finn, Neil A O'Brien, Erika von Euw, Megan M Price, Diego Martinez, Lisa Yonemoto, Meghan Brennan, John A Glaspy, Dennis J Slamon
Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Neil A O'Brien, Martina S J McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J Slamon
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast cancer research : BCR 22 (1) (2020)

Neil A O'Brien.css-eqlu8i{font-size:small;padding-left:4px;} (Neil O'Brien)

Publication Activity (10 Years)

Top Topics

Top Venues

Neil A O'Brien (Neil O'Brien)